[33] fused tumor-derived exosome and CC-chemokine receptor 7 (CCR7) retained DC membrane vesicle to develop a hybrid nanovaccine (Hy-M-Exo) for HNSCC therapy (Fig. 6A). The gene discussed is CCR7; the disease is neoplasm.